<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161583">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02087995</url>
  </required_header>
  <id_info>
    <org_study_id>PTL901100</org_study_id>
    <nct_id>NCT02087995</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm</brief_title>
  <official_title>Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DexCom, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the performance of the Dexcom G4 Platinum with a Modified Algorithm continuous
      monitoring system when compared to a laboratory reference measurement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study to evaluate the performance of a modification to the G4 Platinum CGM system in
      adults with diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>The percentage of agreement of the System compared to a laboratory reference measurement.</measure>
    <time_frame>7-day wear period</time_frame>
    <safety_issue>No</safety_issue>
    <description>the proportion of System values that are within 20% of the reference value for YSI glucose levels &gt; 80 mg/dL or within 20 mg/dL at the reference glucose levels &lt; 80 mg/dL.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CGM System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-Arm, CGM Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring</intervention_name>
    <description>A prescribed clinic session day for participating subjects.</description>
    <arm_group_label>CGM System</arm_group_label>
    <other_name>CGM System</other_name>
    <other_name>G4 Platinum CGM System</other_name>
    <other_name>Dexcom G4 CGM System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 years or older

          -  Diagnosis of Type 1 diabetes or Type 2 diabetes on Intensive Insulin Therapy (ITT)

          -  Willing to participate in a clinic session

        Exclusion Criteria:

          -  Use of Acetaminophen during study period

          -  Pregnancy

          -  Hematocrit (HCT) &lt;35% (females) and 38% (males)

          -  Dialysis, history of cardiovascular disease, epilepsy, severe migraines in the past 6
             months, adrenal disease, syncope, significant hypoglycemia unawareness, or a history
             of severe hypoglycemia within the last 6 months.

          -  Any condition that, in the opinion of the Investigator, would interfere with their
             participation in the study or pose and excessive risk to study staff.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>John Muir Physician Network Clinical Research</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>February 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
